Combination use of anti-CD133 antibody and SSA lectin can effectively enrich cells with high tumorigenicity

Kenta Moriwaki, Kumiko Okudo, Naotsugu Haraguchi, Shunsaku Takeishi, Hiromichi Sawaki, Hisashi Narimatsu, Masahiro Tanemura, Hideshi Ishii, Masaki Mori, Eiji Miyoshi

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)


Glycans exhibit characteristic changes in their structures during development and thus have been used as markers for stem/progenitor cells. However, the glycan structures unique to cancer stem cells (CSC) remain unknown. In the present study, we examined glycan structures in CD133+CD13+ CSC, which were recently found to have a high CSC ability, by means of a lectin microarray. Seven sialylated glycan-recognizing lectins, MAL-I, SNA, SSA, TJA-I, ACG, ABA and MAH, showed higher affinity to CD133+CD13+ CSC than CD133+ cells with a lower CSC ability. In addition, we demonstrated that CD133+SSA+ cells isolated from Huh7 cells had a significantly higher ability to form tumors in non-obese diabetic/severe combined immunodeficiency disease (NOD/SCID) mice and spheres under serum-free conditions than CD133+SSA- cells. These results suggest that hepatic CSC highly express sialylated glycans and that SSA lectin can be used as a tool for isolating CSC. This study is the first report to demonstrate the characteristic glycan structures in CSC and to indicate a new methodology involving lectins for isolating CSC.

Original languageEnglish
Pages (from-to)1164-1170
Number of pages7
JournalCancer Science
Issue number6
Publication statusPublished - Jun 2011
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Combination use of anti-CD133 antibody and SSA lectin can effectively enrich cells with high tumorigenicity'. Together they form a unique fingerprint.

Cite this